Lumykras 240 mg
As listed in the register: Lumykras 240 mg, filmomhulde tabletten
240 mg · filmomhulde tablet
- Prescription only
- Cancer treatments and immune-system medicines
- Active substance
- Sotorasib
- Made by
- Amgen Europe B.V.
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
Mediclarum has not yet retrieved and stored the official label for this product, so none of its text is shown here. Open the official leaflet
How it works
From the US prescribing label for the same active substance (LUMAKRAS). It describes the substance, not this exact product.
Sotorasib is an inhibitor of KRAS G12C, a tumor-restricted, mutant-oncogenic form of the RAS GTPase, KRAS.
Sotorasib forms an irreversible, covalent bond with the unique cysteine of KRAS G12C, locking the protein in an inactive state that prevents downstream signaling without affecting wild-type KRAS.
The main metabolic pathways of sotorasib are non-enzymatic conjugation and oxidative metabolism with CYP3As.
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2025-01-22
Safety of the active substance
From the US prescribing label for the same active substance (LUMAKRAS). It describes the substance, not this exact product.
The most common adverse reactions (≥ 20%) were diarrhea, musculoskeletal pain, nausea, fatigue, hepatotoxicity, and cough.
Quoted from the US prescribing label for the same active substance. Your own pack’s leaflet is the authority for your product. DailyMed
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
European UnionNo exact match for this strength and form
Spain1 matching products
FranceNo exact match for this strength and form
Details
| Made by | Amgen Europe B.V. |
|---|---|
| Active substance | Sotorasib |
| Used in | Cancer treatments and immune-system medicines |
| Strength | 240 mg |
| Form | filmomhulde tablet |
| Classification | L01XX73 · Cancer treatments and immune-system medicines |
| Route | oraal gebruik |
| Dispensing (as stated by the register) | Uitsluitend recept |
| Name in the register | Lumykras 240 mg, filmomhulde tabletten |
| RVG | EU/1/21/1603 |
Source: Geneesmiddeleninformatiebank · 2026-09-30 · not reviewed by a clinician
Bron: College ter Beoordeling van Geneesmiddelen (CBG). De Rijksoverheid is het niet automatisch eens met de inhoud van deze site. Reuse terms: CC0 1.0 (CBG website).
Same active substance
These contain the same substance. That does not mean one can replace another — ask a pharmacist.